# OPTIC RCC (NCT05361720)

> Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

No report yet. It can be ordered.

- Drugs tested: nivolumab plus ipilimumab; nivolumab plus cabozantinib
- Indication: advanced or metastatic clear cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05361720
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Vanderbilt-Ingram Cancer Center
- Conditions: Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
- Interventions: Cabozantinib; Ipilimumab; Nivolumab
- Enrollment: 54
- Primary outcome: Overall response rate (ORR) (Arm 1)
- Primary outcome: Overall response rate (Arm 2)

## Indexed commentary on OPTIC RCC so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 22
- YouTube: 8
- Podcasts: 4
- Bluesky threads: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=optic-rcc-nct05361720

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05361720", "email": "<work email>"}; the inbox owner confirms by the emailed link.